← Volver a la portada
Estados Unidos · Plataformas y datos · Yahoo Finance

Vicore Pharma to Participate in the DNB Carnegie Nordic Healthcare Conference

Publicado por Yahoo Finance · Estados Unidos hace 9 h
ACCESS Newswire · Vicore Pharma Holding
ACCESS Newswire · Vicore Pharma Holding · Yahoo Finance

Resumen detallado

STOCKHOLM, SE / ACCESS Newswire / / AB (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists,…

STOCKHOLM, SE / ACCESS Newswire / November 17, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists, today announced that the company will participate in the DNB Carnegie Nordic Healthcare Conference.

Panel: Idiopathic Pulmonary Fibrosis | Three shots at reversing IPF - the Nordic fibrosis race

For further information, please contact:Hans Jeppsson, Chief Financial Officer, +46 (0)70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma Holding ABVicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small-molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designations from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

AttachmentsVicore Pharma to Participate in the DNB Carnegie Nordic Healthcare Conference

Inicio del artículo, extracto de Yahoo Finance. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en Yahoo Finance Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)

También te puede interesar